The key elements of the symposium comprise the fact that for biosimilars--as opposed to generic small molecules--apart from comparable bioavailability also efficacy and safety data are required by registration authorities. Moreover, the importance of transgenic animals in efficacy and safety testing was treated as well as the different forms of immunotoxicity of biopharmaceuticals. Transgenic animals can also be used for the detection of aggregates of a biopharmaceutical. Finally, referral was made to the post-cytokine storm-incident (TGN1412)-developed first-in-human guideline, in which is prescribed that future clinical trials with biopharmaceuticals should start with a low dose, the MABEL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejps.2008.04.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Integrated Molecule Based on Ferritin Nanoplatforms for Inducing Tumor Ferroptosis with the Synergistic Photo/Chemodynamic Treatment.
ACS Appl Mater Interfaces
January 2025
Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, The Tenth Affiliated Hospital (Dongguan People's Hospital), Southern Medical University, Dongguan, Guangdong 523058, China.
Ferroptosis combined with photodynamic therapy (PDT) has emerged as a powerful approach to induce cancer cell death by producing and accumulating lethal reactive oxygen species (ROS) in the tumor microenvironment (TME). Despite its efficacy and safety, challenges persist in delivering multiple drugs to the tumor site for enhanced antitumor efficacy and improved tissue targeting. Hence, we designed a method of inducing ferroptosis through laser-mediated and human homologation-specific efficient activation, which is also a ferroptosis therapy with higher safety through ROS-mediated.
View Article and Find Full Text PDFRenal Denervation: Antihypertensive Therapy or Gizmo Idolatry?
J Am Coll Cardiol
January 2025
Department of BioMedical Research, University of Bern, Bern, Switzerland. Electronic address:
Comparison of Clazosentan and Nimodipine on Vasospasm and Vasospasm-Related Outcomes after Aneurysmal Subarachnoid Hemorrhage : A Post-hoc Propensity Score-Matched Analysis of Six Randomized Clinical Trials.
J Korean Neurosurg Soc
January 2025
Department of Neurosurgery, Bucheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Objective: Clazosentan is a recently approved endothelin receptor antagonist indicated for the prevention of vasospasm and related complications following aneurysmal subarachnoid hemorrhage (aSAH). To date, no direct, head-to-head comparison between clazosentan and nimodipine has been conducted. In this study, we indirectly assessed the efficacy and safety of these two drugs in preventing vasospasm and its associated outcomes after aSAH.
View Article and Find Full Text PDFDevelopment of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFEfficacy and safety of chemotherapy combined with iodine-125 seed brachytherapy for intermediate and advanced oncogenic driver gene-negative non-small cell lung cancer.
Brachytherapy
January 2025
Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of life Sciences and Medicine, University of Science and Technology, Hefei, Anhui 230022, PR China. Electronic address:
Purpose: To compare the effectiveness and safety of CT-guided iodine-125 seed brachytherapy in conjunction with chemotherapy against chemotherapy alone for the management of intermediate and advanced non-small cell lung cancer (NSCLC) lacking oncogenic driving genes.
Methods And Materials: Retrospective analysis was conducted on clinical data from 128 patients diagnosed with intermediate and advanced non-small cell lung cancer who received iodine-125 combined with chemotherapy or chemotherapy alone due to the absence of oncogenic driver gene mutations. The patients in two groups were compared at 6-month follow-up for objective remission rate (ORR), Disease control rate (DCR), local progression-free survival (LPFS), overall survival (OS), clinical symptom improvement, and adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!